Stockreport

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

Maze Therapeutics, Inc.  (MAZE) 
PDF SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small mol [Read more]